Renal Division, Peking University First Hospital, Peking University Institute of Nephrology; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, 100034, People's Republic of China.
Renal Pathology Center, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
BMC Nephrol. 2020 Nov 26;21(1):514. doi: 10.1186/s12882-020-02175-z.
A renal biopsy is needed to define active inflammatory infiltration and guide therapeutic management in drug-induced acute tubulointerstitial nephritis (D-ATIN). However, factors such as various contraindications, refusal of informed consent and limited technical support may stop the biopsy process. It is thus of great importance to explore approaches that could deduce probable pathologic changes.
A total of 81 biopsy-proven D-ATIN patients were enrolled from a prospective cohort of ATIN patients at Peking University First Hospital. The systemic inflammation score (SIS) was developed based on the CRP and ESR levels at biopsy, and patients were divided into high-SIS, median-SIS, and low-SIS groups. The demographic data, clinicopathologic features, and renal outcomes were compared.
The SIS was positively correlated with inflammatory cell infiltration and was inversely correlated with interstitial fibrosis. The number of interstitial inflammatory cells increased significantly with increasing SISs. The proportions of neutrophils and plasma cells were the highest in the high-SIS group compared with the other two groups. Prednisone (30-40 mg/day) was prescribed in all patients. The high-SIS group tended to have more favorable renal restoration than the other two groups. By 12 months postbiopsy, a decreased eGFR (< 60 mL/min/1.73 m) was observed in 66.7% of medium-SIS patients, 32.4% of high-SIS patients, and 30.4% of low-SIS patients.
The SIS was positively correlated with active tubulointerstitial inflammation and therefore could help to aid therapeutic decisions in D-ATIN.
肾活检对于明确药物诱导的急性肾小管间质性肾炎(D-ATIN)的活动性炎症浸润并指导治疗管理非常必要。然而,由于各种禁忌证、拒绝知情同意书以及有限的技术支持等因素,活检过程可能会受阻。因此,探索能够推断出可能的病理变化的方法非常重要。
本研究共纳入了 81 例经肾活检证实的 D-ATIN 患者,这些患者均来自北京大学第一医院的 ATIN 患者前瞻性队列研究。基于活检时 CRP 和 ESR 水平,建立了系统炎症评分(SIS),并将患者分为高 SIS、中 SIS 和低 SIS 组。比较了三组患者的人口统计学资料、临床病理特征和肾脏结局。
SIS 与炎症细胞浸润呈正相关,与间质纤维化呈负相关。间质炎症细胞数量随 SIS 的增加而显著增加。与另外两组相比,高 SIS 组的中性粒细胞和浆细胞比例最高。所有患者均接受了泼尼松(30-40mg/天)治疗。与另外两组相比,高 SIS 组的肾脏恢复趋势更好。在活检后 12 个月时,中 SIS 组、高 SIS 组和低 SIS 组分别有 66.7%、32.4%和 30.4%的患者出现 eGFR(<60ml/min/1.73m)下降。
SIS 与活动性肾小管间质性炎症呈正相关,因此有助于指导 D-ATIN 的治疗决策。